These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21298814)

  • 21. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.
    Schneeweiss S; Doherty M; Zhu S; Funch D; Schlienger RG; Fernandez-Vidaurre C; Seeger JD
    Dermatology; 2009; 219(1):7-21. PubMed ID: 19293564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pimecrolimus cream 1%: a new development in nonsteroid topical treatment of inflammatory skin diseases.
    Hebert AA; Warken KA; Cherill R
    Semin Cutan Med Surg; 2001 Dec; 20(4):260-7. PubMed ID: 11770913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Letter: Tinea faciei exacerbated by topical immunomodulation: Two case reports].
    Ruiz-Villaverde R; Sanchez-Cano D
    Dermatol Online J; 2010 Mar; 16(3):14. PubMed ID: 20233571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Topical immune modulation and risk of cancer].
    Deleuran M; Zachariae C; Thestrup-Pedersen K
    Ugeskr Laeger; 2009 Aug; 171(35):2468-71. PubMed ID: 19732533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Black box warning for topical calcineurin inhibitors and the death of common sense.
    Fleischer AB
    Dermatol Online J; 2006 Oct; 12(6):2. PubMed ID: 17083882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current concepts and review of pimecrolimus in the treatment of psoriasis.
    Wolff K
    Dermatol Clin; 2004 Oct; 22(4):461-5, ix-x. PubMed ID: 15450341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of topical calcineurin inhibitors in atopic dermatitis.
    Alomar A; Berth-Jones J; Bos JD; Giannetti A; Reitamo S; Ruzicka T; Stalder JF; Thestrup-Pedersen K;
    Br J Dermatol; 2004 Dec; 151 Suppl 70 Dec 2004():3-27. PubMed ID: 15548171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Continued use of nonsteroidal topical treatments: comment on the FDA talk paper.
    Wolf R; Parish JL; Marcus BS; Parish LC
    Skinmed; 2005; 4(3):133-4. PubMed ID: 15891246
    [No Abstract]   [Full Text] [Related]  

  • 29. [Topical pimecrolimus and tacrolimus and the risk of cancer].
    Sánchez-Pérez J
    Actas Dermosifiliogr; 2007 Jun; 98(5):312-7. PubMed ID: 17555673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of topical tacrolimus and pimecrolimus to treat psoriasis: a review.
    Scheinfeld N
    Dermatol Online J; 2004 Jul; 10(1):3. PubMed ID: 15347485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Focal hypertrichosis during topical tacrolimus therapy for childhood vitiligo.
    Prats Caelles I; Herranz Pinto P; de Ayala Casado EL; de Lucas Laguna R
    Pediatr Dermatol; 2005; 22(1):86-7. PubMed ID: 15660910
    [No Abstract]   [Full Text] [Related]  

  • 32. Rosaceiform dermatitis associated with topical tacrolimus treatment.
    Fujiwara S; Okubo Y; Irisawa R; Tsuboi R
    J Am Acad Dermatol; 2010 Jun; 62(6):1050-2. PubMed ID: 20466178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application.
    Weiss HM; Fresneau M; Moenius T; Stuetz A; Billich A
    Drug Metab Dispos; 2008 Sep; 36(9):1812-8. PubMed ID: 18524871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study.
    Papp KA; Werfel T; Fölster-Holst R; Ortonne JP; Potter PC; de Prost Y; Davidson MJ; Barbier N; Goertz HP; Paul C
    J Am Acad Dermatol; 2005 Feb; 52(2):240-6. PubMed ID: 15692468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topical pimecrolimus and tacrolimus do not accelerate photocarcinogenesis in hairless mice after UVA or simulated solar radiation.
    Lerche CM; Philipsen PA; Poulsen T; Wulf HC
    Exp Dermatol; 2009 Mar; 18(3):246-51. PubMed ID: 19183401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is topical tacrolimus really an effective therapy for Hailey-Hailey disease?
    Laffitte E; Panizzon RG
    Arch Dermatol; 2004 Oct; 140(10):1282. PubMed ID: 15492199
    [No Abstract]   [Full Text] [Related]  

  • 37. Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns.
    Wooltorton E
    CMAJ; 2005 Apr; 172(9):1179-80. PubMed ID: 15817641
    [No Abstract]   [Full Text] [Related]  

  • 38. [Pimecrolimus (SDZ ASM 981). Current state of research].
    Dissemond J; Goos M; Wagner SN
    Dtsch Med Wochenschr; 2002 May; 127(22):1199-203. PubMed ID: 12035117
    [No Abstract]   [Full Text] [Related]  

  • 39. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis.
    Prescrire Int; 2004 Dec; 13(74):209-12. PubMed ID: 15599989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases.
    Bornhövd E; Burgdorf WH; Wollenberg A
    J Am Acad Dermatol; 2001 Nov; 45(5):736-43. PubMed ID: 11606925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.